Group 1 - The forum held on November 18 in Wuxi attracted over 700 guests, including executives from more than 30 Fortune 500 companies, focusing on key industries like new energy and biomedicine [1] - A total of 21 high-level R&D projects were signed at the event, alongside the launch of two major industry platforms: the Jiangsu Province Biomedicine Full Industry Chain Open Innovation Alliance and the Jiangsu Province New Energy Industry Chain Hub Platform [1][6] - Jiangsu's actual foreign investment reached $103.74 billion from 2021 to 2024, with a national share of 16.4% in 2024, increasing to 18.1% in the first three quarters of this year [2] Group 2 - The Jiangsu Free Trade Zone's biomedicine open innovation development plan was approved, making it the first province in China to pilot in this field, featuring 18 policy measures and 77 specific tasks [3] - The plan aims to create a "highway" for the entire process of drug development, manufacturing, circulation, and use, with significant cost savings and faster customs clearance [3] - The presence of over 40% of Apple's core suppliers in China, with half located in Jiangsu, highlights the region's mature industrial chain [4] Group 3 - Pfizer announced the launch of the "Pfizer-Jiangsu Full Industry Chain Innovation Empowerment Plan" to deepen its involvement in Jiangsu's biomedicine sector [5] - LG Group has invested nearly $10 billion in Jiangsu, viewing it as a key base for new energy battery production, with plans for further investment in new technologies [5] - The establishment of two major industry platforms aims to enhance collaborative efficiency and international competitiveness in key sectors like power batteries and renewable energy [6] Group 4 - Eli Lilly plans to deepen local cooperation in major disease areas, having invested a total of $15 billion in its Suzhou pharmaceutical production base over the past 30 years [7]

Core Insights - VAREX IMAGING reported revenue of $228.9 million for the quarter ended September 2025, reflecting an 11.3% increase year-over-year and surpassing the Zacks Consensus Estimate of $220.45 million by 3.83% [1] - The company's EPS for the quarter was $0.37, significantly higher than the $0.19 reported in the same quarter last year, and exceeded the consensus EPS estimate of $0.18 by 105.56% [1] Revenue Breakdown - Industrial revenue reached $76.8 million, exceeding the average estimate of $65.39 million by analysts, marking a 25.3% increase compared to the previous year [4] - Medical revenue was reported at $152.1 million, slightly below the average estimate of $155.08 million, but still showing a year-over-year increase of 5.3% [4] Profit Metrics - Gross profit from Industrial operations was $29.8 million, surpassing the average estimate of $22.05 million [4] - Gross profit from Medical operations was $48 million, which was below the average estimate of $49.24 million [4] Stock Performance - Over the past month, VAREX IMAGING shares have returned -1.7%, contrasting with a +0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - The forum held on November 18 in Wuxi focused on international cooperation in supply chains, attracting over 700 attendees, including executives from more than 30 Fortune 500 companies [1] - Key discussions revolved around the collaborative development of supply chains in critical industries such as renewable energy and biomedicine, leading to the signing of 21 high-level R&D projects [1][6] - Jiangsu province has achieved significant foreign investment, with actual foreign capital usage reaching $103.74 billion from 2021 to 2024, accounting for 16.4% of the national total in 2024 [2] Industry Developments - The establishment of the "Jiangsu Province Biomedicine Full Industry Chain Open Innovation Alliance" and the "Jiangsu Province New Energy Industry Chain Hub Platform" aims to enhance global resource connectivity and build a new industrial ecosystem [1][6] - The "Jiangsu Free Trade Zone Biomedicine Full Industry Chain Open Innovation Development Plan" has been approved, making Jiangsu the first province in China to pilot in the biomedicine sector, featuring 18 policy measures to streamline the R&D process [3] Company Engagements - GE Healthcare's Wuxi base has become the largest ultrasound equipment center globally, supporting over 460 upstream and downstream suppliers, showcasing the strength of the industrial cluster [2] - Pfizer announced the launch of the "Pfizer-Jiangsu Full Industry Chain Innovation Empowerment Plan" to deepen its involvement in Jiangsu's biomedicine sector, emphasizing local production and global market integration [5][7] - Apple’s core suppliers, over 80% of whom have factories in China, with half located in Jiangsu, highlight the region's mature industrial chain and advancements in smart manufacturing and green transformation [4]

Financial Data and Key Metrics Changes - Fourth Quarter revenue was $229 million, up 11% year over year, at the high end of guidance [5][6] - Non-GAAP gross margin for the Fourth Quarter was 34%, 130 basis points higher than the same quarter last year [6][14] - Non-GAAP earnings per share in the Fourth Quarter was $0.37, up $0.21 compared to last year [6] - Total revenue for Fiscal Year 2025 was $845 million, a 4% increase compared to Fiscal Year 2024 [6] - Non-GAAP EBITDA for the year was $122 million, up $33 million from $89 million last year [6][15] Business Line Data and Key Metrics Changes - Medical segment revenue increased by 5% year over year, totaling $152 million in the Fourth Quarter [11][12] - Industrial segment revenue grew by 25% year over year, reaching $77 million in the Fourth Quarter, marking the highest quarterly contribution of industrial revenue in Varex's history [11][12] - For the full fiscal year, medical revenue was $593 million, a 2% increase year over year, while industrial revenue was $252 million, a 10% increase [6][11] Market Data and Key Metrics Changes - Revenue from the Americas grew by 9%, EMEA rose by 16%, and APAC increased by 8% year over year [13] - Sales volume to China remained steady, contributing 14% of total revenues, reflecting resilience in the healthcare market despite tariff challenges [13][21] Company Strategy and Development Direction - The company plans to invest in R&D to strengthen its competitive edge and focus on growth markets such as India, South Asia, the Middle East, and Latin America [22][23] - Varex is advancing its photon counting CT technology and expanding its manufacturing capabilities in India to support cost-effective product designs [22][23][25] - The company aims to lead with innovation while maintaining cost-effectiveness in the value and mid-tier segments [22] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging start to Fiscal Year 2025 due to global tariff situations, but customer ordering patterns have normalized [21] - Customers in China are projecting stronger orders for 2026 compared to 2024 and 2025, driven by demand for value tier and mid-tier CT systems [21] - The company is intensifying efforts to strengthen geopolitical resiliency through supply chain and manufacturing regionalization [21][22] Other Important Information - The company ended the year with $155 million in cash, cash equivalents, and marketable securities, down from $213 million last year due to debt retirement [6][18] - Gross debt outstanding at the end of the quarter was $370 million, with a net debt leverage ratio of approximately 1.8 times adjusted EBITDA [18][19] Q&A Session Summary Question: Can you split the top 10 customers' contribution between medical and industrial? - Management stated that the top 10 customers generally account for 50%-55% of sales, primarily from the medical segment, but they do not disclose the split for commercial reasons [30][31] Question: Is there a structural shift in the medical and industrial segments? - Management indicated that industrial sales are growing and expected to reach mid-30s as a percentage of overall sales, while medical segment volatility is influenced by geopolitical factors [32][33] Question: What are the implications of GE and Siemens Healthineers divesting their China business? - Management noted that most business in China comes through Chinese OEMs, so these announcements do not have significant implications for Varex [36][37] Question: Can you provide a high-level outlook for the full year? - Management expects solid demand and growth in both medical and industrial segments, with medical business ex-China anticipated to grow [40][41] Question: What is the impact of tariffs on gross margin? - Management indicated that tariffs impact gross margin by 100 to 150 basis points, and they are working to mitigate this through supply chain adjustments [82][83]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $229 million, an increase of 11% year-over-year, and at the high end of guidance [5][6] - Non-GAAP gross margin for the fourth quarter was 34%, up 130 basis points from the same quarter last year [6][14] - Non-GAAP earnings per share in the fourth quarter was $0.37, up $0.21 compared to last year [6] - For the full fiscal year, total revenue was $845 million, a 4% increase compared to fiscal 2024 [6] - Non-GAAP EBITDA for the year was $122 million, up $33 million from $89 million last year [6] Business Line Data and Key Metrics Changes - Medical segment revenue increased by 5% year-over-year to $152 million in the fourth quarter, while Industrial segment revenue surged by 25% to $77 million [11][12] - For the full year, Medical revenue was $593 million, a 2% increase, and Industrial revenue was $252 million, a 10% increase [6][11] - The Industrial segment achieved its highest revenue quarter ever at $77 million, driven by strong demand for security inspection systems [5][7] Market Data and Key Metrics Changes - Revenue from the Americas grew by 9%, EMEA rose by 16%, and APAC increased by 8% year-over-year [13] - Sales volume to China remained steady, contributing 14% of total revenues, reflecting resilience in the healthcare market despite tariff challenges [13][21] Company Strategy and Development Direction - The company plans to focus on innovation and cost-effectiveness in the value tier and mid-tier segments, particularly in emerging markets like India, South Asia, and Latin America [22][23] - Investments in supply chain and manufacturing regionalization are aimed at strengthening geopolitical resiliency [21][22] - The company is advancing its Photon Counting CT project and expanding production capabilities in India [23][25] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging start to fiscal 2025 due to global tariff situations, but customer ordering patterns have normalized [21] - Expectations for stronger orders and sales in China for 2026 compared to previous years were expressed [21] - The company anticipates gradual growth throughout fiscal 2026, with Medical business expected to grow and Industrial business also projected to increase [41][42] Other Important Information - The company ended the year with $155 million in cash, down from $213 million the previous year, primarily due to debt reduction efforts [6][18] - The company reported a non-cash goodwill impairment charge of $94 million taken in Q3, impacting operating income [14] Q&A Session Summary Question: Can you split the top 10 customers' contribution between Medical and Industrial? - Management indicated that the top 10 customers generally contribute 50%-55% of sales, primarily from the Medical segment, but did not provide a specific breakdown for commercial reasons [30][31] Question: Is there a structural shift in Medical and Industrial segments? - Management noted that Industrial sales are growing and approaching 30% of overall sales, while Medical segment volatility is influenced by geopolitical factors [32][33] Question: Any implications from GE or Siemens Healthineers divesting their China business? - Management stated that the majority of business in China comes from Chinese OEMs, and they do not anticipate significant impacts from these potential divestitures [36][37] Question: Can you provide a high-level outlook for the full year? - Management expects solid demand and growth in both Medical and Industrial segments, with China modeled to be stable [40][41] Question: What is the impact of tariffs on gross margin? - Management indicated that tariffs are impacting gross margin by 100 to 150 basis points, but efforts to reroute supply chains and increase production in India may help mitigate this [81][82]

Core Insights - IceCure Medical Ltd. specializes in cryoablation technology, a minimally-invasive method for tumor destruction through freezing, and is set to release quarterly earnings on November 19, 2025, with Wall Street expecting an EPS of -$0.05 and revenue of approximately $714,000 [1] Financial Performance - The company has a negative price-to-earnings (P/E) ratio of -2.67, indicating negative earnings, and a negative earnings yield of -37.46%, highlighting ongoing financial difficulties [2] - ICCM's price-to-sales ratio stands at 17.53, suggesting that investors are willing to pay $17.53 for every dollar of sales [2] - The enterprise value to sales ratio is 16.45, slightly lower than the price-to-sales ratio, reflecting the company's valuation including its debt [3] - The enterprise value to operating cash flow ratio is -3.23, indicating challenges in generating positive cash flow from operations [3] Debt and Liquidity - ICCM has a debt-to-equity ratio of 0.82, showing a moderate level of debt compared to its equity, indicating that the company is not overly reliant on debt for financing [4] - The current ratio of 1.18 suggests that ICCM has a reasonable level of liquidity to cover its short-term liabilities, providing some financial stability amidst its challenges [4]

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Founded**: 17 years ago by Moshe Mizrahy - **Headquarters**: Israel - **Employees**: 650 worldwide, plus 200 in manufacturing - **Revenue Growth**: From $22 million in 2017 to $500 million in 2023, indicating rapid growth [7][20] Core Business and Technology - **Focus**: Aesthetic and wellness medical treatments, utilizing minimally invasive technology rather than traditional optical energy methods [6][8] - **Key Products**: - BodyTite platforms for fat melting and skin tightening - Empower for women's health, targeting vaginal laxity and urinary incontinence - InVision for dry eye treatment [7][12][13] Market Dynamics - **Current Market Challenges**: - Revenue decline of 20% expected in 2024 due to high inflation (8%-9%) and increased interest rates (13%-14%) affecting equipment financing for doctors [19][20] - Projected revenue for 2023 is approximately $370 million [20][21] - **Gross Margin**: Maintained at 80% despite market challenges, with EBITDA above 20% [20] Future Growth Opportunities - **Women's Health**: - Ongoing FDA studies for urinary incontinence and overactive bladder, expected to complete by end of 2026 [11][14] - Empower product generated $40 million in its first year [12] - **Ophthalmology**: - InVision product for dry eye treatment sold $30 million in its first year, with expectations to exceed $50 million annually in the future [13] - **International Expansion**: - Established subsidiaries in Japan, Argentina, and Thailand, aiming to increase direct sales from 80% to 85% [22][24] - Potential growth in China, with plans to expand product offerings as additional clearances are obtained [24][38] Sales and Marketing Strategy - **Sales Force**: - Approximately 300 direct salespeople globally, with 210 in the U.S. [30] - Leadership changes made to streamline management and improve sales momentum [31][32] - **Marketing Investments**: Increased spending on marketing to support direct sales efforts [22] Financial Strategy - **Capital Allocation**: - $508 million spent on stock buybacks, with a shift in focus towards exploring M&A opportunities [33][34] - No current M&A pipeline, but interest in acquiring companies related to women's health and wellness [34] Product Development - **Upcoming Products**: - Development of four laser types (CO2, Erbium, Q-Switch, PICO) to complement existing RF technology, expected to launch between 2026 and 2027 [35][36] Conclusion - InMode is navigating a challenging market environment but remains optimistic about future growth through product innovation, international expansion, and strategic management of its sales force and financial resources [20][21][22]

Core Viewpoint - Medtronic's stock surged over 6% to reach a nearly four-year high following the release of its Q2 fiscal 2026 earnings, which exceeded analyst expectations [1] Financial Performance - Medtronic reported net sales of $8.96 billion for Q2, surpassing the analyst forecast of $8.87 billion [1] - Adjusted earnings per share were $1.36, higher than the expected $1.31 [1] - The cardiovascular segment saw a year-over-year sales increase of 10.8%, reaching $3.44 billion [1] Future Outlook - For the full fiscal year 2026, Medtronic raised the lower end of its adjusted earnings per share guidance from $5.60 to $5.62, while maintaining the upper end at $5.66 [1] - The company also increased its organic revenue growth forecast from approximately 5% to about 5.5% for the year [1]

Major Events - Universal Medical (02666) plans to invest 15.03 million yuan to establish a joint venture that will create a collaborative platform integrating policy alignment, technology transfer, and clinical validation [1] - Fosun Pharma (02196) subsidiary has had its drug registration application for polyethylene glycol electrolyte solution accepted by the National Medical Products Administration [1] - China Biologic Products (01177) received approval from NMPA for the clinical trial application of LM-350 "CDH17 ADC" [1] - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration for the registration of its coronary overall exchange balloon dilation catheter [1] - Meili Tianyuan Medical Health (02373) subsidiary plans to acquire medical and beauty assets related to Nairuier for 40 million yuan, adding 19 direct-operated stores [1] - China Tongru (01763) has exported its self-produced irradiation equipment to the Latin American market for the first time [1] Operating Performance - Trip.com Group-S (09961) reported a third-quarter net profit of 19.89 billion yuan, an increase of 194.01% year-on-year [1] - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the first three quarters [1] - Weibo-SW (09898) reported a net profit attributable to shareholders of 454 million USD for the third quarter, an increase of 55.43% year-on-year [1] - Baidu Group-SW (09888) reported total revenue of 31.2 billion yuan in the third quarter, with AI new business revenue growing over 50% year-on-year [1] - Xiaomi Group-W (01810) achieved a record adjusted net profit of 11.31 billion yuan in the third quarter, with smartphone shipments increasing year-on-year for nine consecutive quarters [1] - China Oriental Group (00581) reported sales of approximately 2.1 million tons of self-produced steel products in the third quarter [1] - BOSS Zhipin-W (02076) reported an adjusted net profit of approximately 999.2 million yuan in the third quarter, an increase of 34.2% year-on-year [1]

Zynex (NasdaqGS:ZYXI) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Speaker2Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Vikram Bajaj, Chief Financial Officer of Zynex. Please go ahead.Speaker1Thank you, Operator, and good afternoon, everyone. Yesterday, we rele ...